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ABSTRACT: High abundant protein depletion is a common
strategy applied to increase analytical depth in global plasma
proteomics experiment setups. The standard strategies for
depletion of the highest abundant proteins currently rely on
multiple-use HPLC columns or multiple-use spin columns. Here
we evaluate the performance of single-use spin columns for plasma
depletion and show that the single-use spin reduces handling time
by allowing parallelization and is easily adapted to a nonspecialized
lab environment without reducing the high plasma proteome
coverage and reproducibility. In addition, we evaluate the effect of
viral heat inactivation on the plasma proteome, an additional step
in the plasma preparation workflow that allows the sample
preparation of SARS-Cov2-infected samples to be performed in a
BSL3 laboratory, and report the advantage of performing the heat inactivation postdepletion. We further show the possibility of
expanding the use of the depletion column cross-species to macaque plasma samples. In conclusion, we report that single-use spin
columns for high abundant protein depletion meet the requirements for reproducibly in in-depth plasma proteomics and can be
applied on a common animal model while also reducing the sample handling time.
KEYWORDS: plasma, high abundant protein depletion, heat-inactivation, biomarkers
■ INTRODUCTION
Analyzing human plasma with modern mass spectrometry
(MS)-based proteomics technologies holds enormous poten-
tial, not only as a source of biomarkers for disease and
treatment, but also to study complex systemic signaling events
that are involved in basic biological processes. However, due to
a range of major analytical challenges, in-depth plasma
proteome studies of large clinical cohorts remain a challenge.
One of the main fundamental differences when applying
proteomics methods to plasma compared to cellular or tissue
material is the presence of a few extremely high abundant
proteins that dominate the protein content and hamper the
detection of other less abundant protein species. Albumin, for
example, has a plasma concentration of 35−50 mg/mL, which
can be compared to the clinically used tissue leakage marker
Prostate Specific Antigen (PSA) that is present in low ng/mL
concentrations. In plasma about 55% of the total protein mass
is made up by albumin alone and as few as seven proteins
together make up 85% of the total protein mass. This can be
compared with estimates from tissue and cellular data where
2300 housekeeping proteins are thought to make up 75% of
the protein mass.1 In addition, there is an enormous variability
between individuals in their composition of the plasma
proteome, attributed both to hereditary as well as environ-
mental and temporal factors,2,3 making robust measurements
and throughput key components in any plasma analysis
workflow.
In general, achieving high plasma proteome coverage using
MS-based technologies is dependent on extensive fractiona-
tion. Consequently, aiming for large proteome coverage comes
at the cost of low sample throughput, and vice versa high-
throughput comes at the cost of limited proteome coverage.
To repetitively identify and quantify a consistent set of
proteins across a large number of samples is of particular
challenge, and the number of proteins identified across all
samples drastically drops in cohorts consisting of more than
100 samples.
With the transition toward personalized medicine, much
effort has been put into adapting MS methods to be applicable
in the clinical setting, focusing on robustness, throughput, and
analytical turnaround time using both data dependent
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(DDA)4−6 and data independent (DIA)7−9 analysis methods.
In parallel, there is a need for in-depth unbiased global
methods for discovery proteomics, enabling discovery of low-
abundant, modified and noncanonical variants of proteins in
plasma. We have previously developed a method for in-depth
plasma proteomics and proteogenomics based high resolution
isoelectric focusing (HiRIEF) peptide fractionation in
combination with high abundant protein depletion and TMT
labeling.10 Using the plasma HiRIEF method we show that we
can detect low abundant tissue leakage proteins as well as
individual specific protein sequence variants transferred across
the placenta during pregnancy. During the development of the
method, we optimized the MS analysis time to improve the
throughput. In addition, we identified the depletion step using
multiple-use HPLC columns as bottleneck. High abundant
protein depletion using antibodies or other affinity resins is one
of the most used prefractionation methods in in-depth plasma
proteomics.11−14 Removing high abundant proteins in a native
setting inevitably coremove additional nontargeted proteins of
potential significance. In addition, the step often requires
subsequent concentration and buffer-exchange steps and is
hence often omitted in studies aiming for high-throughput.
However, the benefit on the number of identified proteins is
well documented and the depletion step remains widely used
in in-depth proteomics.5,10,15
Examples of depletion systems include multiple-use HPLC
columns for removal of up to 14 proteins,10,16 IgY ultra high
depletion columns,15 and multiple-use spin columns.
HPLC based depletion systems have the benefit of being
automated, providing a robust platform for depletion.
However, not every laboratory has access to the required
equipment and, in addition to the analysis time setting up the
system, HPLC washes and maintenance limits the throughput.
Multiple-use spin columns for high abundant protein depletion
have been available for a long time, with the disadvantage of a
reduced throughput due to limitations in parallelization.
Recently, single-use depletion spin columns have been
developed (i.e., High Select Top14 Abundant Protein
Depletion Mini Spin Columns, Thermo) that greatly reduce
the handling time compared to HPLC columns and enable
parallel depletion of multiple samples, which has not been
possible with the previous multiple-use columns. Also, the
COVID-19 pandemic has highlighted the need for a depletion
protocol easily adapted in a BSL3 facility without the need for
special equipment such as an HPLC system, as heat
inactivation of the virus prior to depletion could affect the
depletion efficacy by disrupting the targeted epitopes.
In the present study, we evaluated the use of single-use spin
columns for high abundant protein depletion prior to in-depth
MS based global plasma analysis, to improve throughput while
maintaining high proteome coverage and high reproducibility.
We compared the depletion efficacy both in relation to virus
heat-inactivation, and cross-species on an animal model
(Figure 1).
■ MATERIALS AND METHODS
Chemicals and Reagents
All chemicals were LC or electrophoresis grade. Dithiothreitol
(DTT), chloroacetamide (2-chloroacetamide), 4-(2-hydrox-
yethyl)-1-piperazineethanesulfonic acid (HEPES), formic acid,
and acetonitrile and urea were purchased from Sigma-Aldrich.
Trypsin Protease, NuPAGE 4−12% Bis-Tris Protein Gels,
MOPS SDS Running Buffer (20×), Sample Reducing Agent
(10×) and LDS Sample Buffer (4×), High Select Top14
Abundant Protein Depletion Mini Spin Columns and Midi
Spin Columns, TMTpro 16 plex kit and TMT10 plex kit were
acquired from Thermo Fisher Scientific. Agilent Plasma 14
Multiple Removal System 4.6 × 100 Hu-14, Buffer A and
Buffer B and 5 kDa molecular weight cut off filter were
obtained from Agilent technologies. Lysyl Endopeptidase R
(Lys-C) was from FUJIFILM Wako Pure Chemical Corpo-
ration. Immobilized pH gradient (IPG) strips and IPG buffers
were purchased from GE Healthcare.
Plasma Sampling
Human Plasma Samples. This study was carried out
according to the Declaration of Helsinki and samples were
anonymized to protect the privacy of the study participants.
After approval by the Stockholm regional ethics board (EPN:
ref no 2014/1290−32), plasma samples were collected from
September 2014−November 2015. Peripheral venous blood
were collected in EDTA tubes (BD Vacutainer K2E 7.2 mg,
BD Diagnostics). EDTA tubes were first centrifuged at 1500g
at 4 °C for 10 min. The supernatant was transferred to a new
tube and centrifuged at 3000g at 4 °C for 10 min. The plasma
was then aliquoted and kept at −80 °C until analysis. Fourteen
plasma samples were randomly chosen for the current plasma
depletion methods evaluation.
Cynomolgus Macaque Plasma Samples. The blood
samples were provided by the Astrid Fagraeus Laboratory,
Karolinska Institutet, Stockholm, Sweden, under the ethical
permit No. 9544−2019. Samples were collected in 4 mL
EDTA tubes (BD Diagnostics), kept at room temperature and
processed within a few hours after collection. EDTA tubes
were first centrifuged at 200g at room temperature for 10 min.
The plasma was transferred to a new Eppendorf microtube and
centrifuged at 1000g at room temperature for 10 min. Plasma
was aliquoted into fresh Eppendorf microtubes and frozen at
−80 °C until analysis.
High Abundant Protein Depletion
Agilent Plasma 14 Multiple Removal System. Agilent
Plasma 14 Multiple Removal System 4.6 × 100 Hu-14 was set
Figure 1. Schematic drawing of workflow(s).
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up on an Agilent HPLC system (Agilent technologies), 40 μL
of plasma were applied to each injection and run according to
the manufacturer’s instructions. The depleted plasma flow-
through was concentrated on 5 kDa molecular weight cut off
filter followed by buffer exchange to 50 mM HEPES pH 7.6 for
the TMT-analysis.
High Select Top14 Abundant Protein Depletion Mini
Spin Columns and Midi Columns. Depletions were
performed according to the manufacturer’s recommendations.
Briefly, 10 μL of plasma were applied to each Mini column
and 40 μL of plasma were applied to each Midi column,
respectively, and incubated at room temperature with gentle
end-over-end mixing, for 20 min. Depleted flowthroughs were
recovered by centrifugation. The depleted plasma flow-through
was concentrated on 5 kDa molecular weight cut off filter
followed by buffer exchange to 50 mM HEPES pH7.6 for the
TMT-analysis.
Heat Treatment. Three aliquots of crude plasma samples
from one healthy donor were heated at 56 °C for 30 min prior
to depletion. In parallel, three depleted aliquots from the same
individual were also heated postdepletion for 30 min at 56 °C.
QC of Depleted Plasma Samples. After protein
concentration measurement, quality check was applied on all
the depleted samples by using ThermoFisher Scientific
NuPAGE protein gel system. Ten micrograms of protein of
each sample were loaded to the gel (Supporting Figure S4)
MS Sample Preparation
Digestion and Labeling. Depleted plasma was denatured
at 60 °C for 1 h followed by reduction with DTT at 95 °C for
30 min and alkylation with chloroacetamide at room
temperature for 20 min at end concentrations of 4 mM.
Trypsin was added at a 1:50 (w/w) ratio and digestion was
performed at 37 °C overnight. When applicable TMTpro-/
TMT-10-plex labeling was performed according to manufac-
turer’s instructions. Labeling efficiency was evaluated by LC-
MS/MS on individual samples using 30 min gradients to
ensure >95% labeling of peptides before pooling. Following
digestion (and labeling if applicable), 1 mL Strata X-C 33u
columns (Phenomenex) were used for sample cleanup. The
peptides were subsequently dried in a speedvac.
HiRIEF Separation. HiRIEF was performed as previously
described.10 Briefly, the samples were rehydrated in 8 M urea
with bromophenol blue and 1% IPG buffer, and subsequently
loaded to the immobilized pH gradient (IPG) strip and run
according to previously published isoelectric focusing (IEF)
protocols.10 After IEF, the IPG strip was eluted into 72
fractions using in-house robot. The obtained fractions were
dried using SpeedVac and frozen at −20 °C until MS analysis.
LC-ESI-MS/MS Q-Exactive HF. Online LC-MS was
performed as previously described10 using a Thermo UltiMate
3000 RSLCnano System coupled to a Q-Exactive-HF Hybrid
Quadrupole-Orbitrap mass spectrometer (Thermo Scientific).
Each of the 72 plate wells was dissolved in 20 μL solvent A and
10 μL were injected. Samples were trapped on a C18 guard-
desalting column (Acclaim PepMap 100, 75 μm × 2 cm,
nanoViper, C18, 5 μm, 100 Å), and separated on a 50 cm long
C18 column (Easy spray PepMap RSLC, C18, 2 μm, 100 Å, 75
μm × 50 cm). The nano capillary solvent A was 95% water, 5%
DMSO, 0.1% formic acid; and solvent B was 5% water, 5%
DMSO, 95% acetonitrile, 0.1% formic acid. At a constant flow
of 0.25 μL min−1, the curved gradient went from 6 to 10% B up
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(see Supporting Table S1), followed by a steep increase to
100% B in 5 min.
FTMS master scans with 60 000 resolution (and mass range
300−1500 m/z) were followed by data-dependent MS/MS
(30 000 resolution) on the top 5 ions using higher energy
collision dissociation (HCD) at 30% normalized collision
energy. Precursors were isolated with a 2 m/z window.
Automatic gain control (AGC) targets were 1 × 106 for MS1
and 1 × 105 for MS2. Maximum injection times were 100 ms
for MS1 and 400 ms for MS2. The entire duty cycle lasted
∼2.5 s. Dynamic exclusion was used with 30 s duration.
Precursors with unassigned charge state or charge state 1 were
excluded. An underfill ratio of 1% was used.
Data Searches. Orbitrap raw MS/MS files were converted
to mzML format using msConvert from the ProteoWizard tool
suite.17 Spectra were searched using the ddamsproteomics
pipeline (v1.5) (DOI 10.5281/zenodo.3714589), which is a
Nextflow18 pipeline runningMSGF+ (2020.03.12),19 Percola-
tor (v3.4).20 All human searches were done against the human
protein coding subset of Ensembl version 92 (107 844 entries),
and macaque samples were searched against UniProt
cynomolgus macaques protein sets (2020−10−01, 46345
entries). MSGF+ settings included precursor mass tolerance
of 10 ppm, fully tryptic peptides, maximum peptide length of
50 amino acids and a maximum charge of 6. Fixed
modifications were TMTpro 16 plex (depletion data) or
TMT 10-plex (heat-inactivation data) on lysines and peptide
N-termini, and carbamidomethylation on cysteine residues, a
variable modification was used for oxidation on methionine
residues. Quantification of TMTpro 16 plex reporter ions was
done using OpenMS project’s IsobaricAnalyzer (v2.5).21 PSMs
found at 1% FDR (false discovery rate) were used to infer gene
identities.
Protein quantification by TMTpro 16 plex reporter ions was
calculated using medians of log2-transformed PSM channel
intensities from which were subtracted the average value of all
channels per PSM. Protein and gene quantification values were
then normalized by subtracting their channel medians. Protein
false discovery rates were calculated using the picked-FDR
method using gene symbols as protein groups and limited to
1% FDR22
Statistical Analyses
Statistical analyses were performed using R (version 4.0.3, R
Core Team, 2017, https://www.R-project.org/) and R Studio
(version 1.3.1093, RStudio Team 2015, http://www.rstudio.
com/). For analysis of differential protein levels between
samples we applied Limma within the DEqMS package23
(version 1.6.0), https://bioconductor.org/packages/release/
bioc/html/DEqMS.html) in R. Correction for multiple testing
was performed using the Benjamini−Hochberg method.
Correlations and associated p-values (Spearman and
Pearson) were calculated using stat_cor in R. Hierarchical
clustering analysis, was performed using Pearson correlation,
and the results visualized in heatmaps using the R-package
pheatmap (version 1.0.12, https://CRAN.R-project.org/
package=pheatmap). Principal components analysis was
performed using either SIMCA software (version 16.0.2,
Umetrics, https://umetrics.com/kb/simca-16), or in R using
prcomp, and the factoextra package (1.0.7, https://CRAN.R-
project.org/package=factoextra) for extracting and visualizing
the results. The PCA was performed on log2 TMT-ratio
intensities. Unit variance scaling was applied. Descriptive
statistics (violin plots and bar charts) were performed using the
software GraphPad Prism (version 9.0.1, https://www.
graphpad.com).
■ RESULTS
Evaluation of Spin Columns vs HPLC Columns
The overall aim of the current project was to explore if single-
use spin columns for high abundant plasma protein depletion
would provide similar depletion efficacy and robustness as
traditional HPLC columns, but at an increased throughput.
The MARS-14 HPLC column (Agilent; from here on denoted
“MARS”), targeting 14 proteins (Table 1), was chosen as gold
standard and compared with two spin columns with different
loading capacity, High Select Top14 Abundant Protein
Depletion Midi Spin Column (from here on denoted
“Midi”) and High Select Top14 Abundant Protein Depletion
Mini Spin Column (from here on denoted “Mini”), both
Thermo Scientific (Table 1).
First, we wanted to explore if the spin columns could
provide the same number of identified proteins as the standard
HPLC column. We decided to evaluate two spin columns with
identical depletion resins, but with different loading capacity:
one with a maximum load of 100 μL plasma (Midi), and one
with maximum load of 10 μL human plasma (Mini). The
potential advantage of the Mini column would be the
microcentrifuge format and the reduced sample volume
needed. To make a head-to-head comparison we loaded the
same amount of plasma (40 μL) on both the MARS-14
column and the Midi spin column (Since we have previously
shown that increased protein load is correlated to high number
of identified proteins10) and 10 μL on the Mini column.
To account for individual variability, an identical set of 14
plasma samples + two pooled internal standards from 14
different individuals were depleted using each column and then
subjected to downstream in-depth plasma HiRIEF LC-MS/MS
using 16-plex TMT labeling as previously described10 (set 1−
set 3, Table 1). On average the protein yield from the Mini,
Midi and MARS-14 was 59, 208, and 137 μg, respectively
(Supporting Table S2). Depletion time for each sample using
the MARS-14 column on a HPLC system was 40 min
(effective depletion time, not including the setup, wash). In
comparison, since several samples can be prepared in parallel
using the spin columns, each TMT-16 plex set with 16 samples
could be depleted during the same time frame using the spin
columns, highlighting the benefit of using single-use spin
columns for increased throughput.
In total 1884 proteins (protein centric, 1% peptide and
protein FDR) were detected using the standard MARS-14
depletion approach loading close to 1 mg total peptide on the
HiRIEF strip, which is in line with the number of proteins
detected per set in previous analyses using same method.10,24
From the Midi spin column 1905 proteins (1% peptide and
protein FDR, 1.06 mg peptide on strip) were identified and
from the Mini spin columns 1931 proteins (1% peptide and
protein FDR, 0.72 mg peptide on strip) (Table 1). This initial
analysis showed that a similar number of identifications could
be obtained using the spin columns as with the traditional
HPLC column and that reducing the sample load from 40 μL
crude plasma to 10 μL plasma did not have a negative effect on
the number of identified proteins.
As the MARS column and the Mini and Midi columns target
a slightly different set of proteins (11 of 14 overlapping), we
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wanted to explore if the different depletion methods
introduced depletion specific batch effect on the samples. To
get an overview of sample similarity/dissimilarity based on
protein expression, principal components analysis was
performed (Figure 2).
Judging from the PCA scores plot, it was evident that the
samples clustered by individual rather than by depletion
method, showing that the type of depletion system did not
greatly affect the data overall. Instead, the individual feature of
each sample was well preserved throughout the three set ups,
showing the robustness of the depletion approach in general.
To further explore the agreement between the three
different depletion methods, the correlations between the
plasma depletion methods were pairwise compared (Mini
versus Midi, Mini versus MARS and Midi versus MARS,
respectively) protein by protein for each of the samples.
Spearman’s correlation coefficients (R2) and statistical
significance were calculated from the points. In brief, median
R2 was for Mini vs Midi: 0.67 (range: 0.63−0.84); Mini vs
MARS 0.68 (range: 0.56−0.83); and for Midi vs MARS: 0.60
(range: 0.51−0.85), Supporting Figure S1, showing that the
overall agreement was similar between the individual methods
regardless of which column was used.
Given that the depletion columns target a slightly different
set of proteins (Table 1), we wanted to further explore if the
specific proteins targeted by the depletion were altered
between the different set-ups. To this end, we visualized the
proteins targeted by either of the depletion methods by violin
plots as shown in Figure 3. Subdividing the targeted proteins
into immunoglobulins (Figure 3B) and other plasma protein
targets (Figure 3C), we could see that the methods differed in
the depletion of immunoglobulins (Figure 3B,C). By visual-
izing the individual protein expression for each method in
boxplots we could see that among the proteins targeted
exclusively by the MARS column (gene names C3, TTR and
APOA2), C3 was below detection level for 2 out of 4 protein
isoforms in the MARS-depleted samples, showing high degree
of variability in the effectiveness of depletion between the
individual isoforms (Supporting Figure S2). APOA2 levels
were also reduced, but to a varying degree between the
samples. Among the proteins listed as targets of depletion
uniquely for the Mini/Midi column (IgE, IgD, and IgG light
chains), it was evident that these were also depleted and even
so to a larger extent, by the MARS column. However, it is
worth noticing that the MARS columns target the IgG protein,
including both heavy and light chains. The levels of IgG kappa
and lambda light chains were in almost all cases below
detection limit in the MARS depleted samples. The proteins
targeted by all three methods were removed equally well across
all three methods.
Overall, these comparisons showed that the depletion
columns performed equally well in terms of number of
identified proteins in the depleted samples (Table 1), and that
neither of the depletion columns had a major impact on the
global protein expression pattern of the samples (Figure 2).
Hence, we chose to move forward with the Mini column, since
it required less material and was easy to use in a normal table-
top microcentrifuge.
Effect of Heat Treatment for Virus Inactivation
The COVID-19 pandemic has highlighted the need of
performing viral inactivation of potentially infected plasma
samples. Heat inactivation is an appealing simple and effective
measure to inactivate the SARS-CoV-2 virus25 and is
commonly used to inactivate other enveloped viruses.
However, heat inactivation of crude plasma samples could
Figure 2. Principal components analysis (PCA) performed on data from the plasma depletion column study in which triplicate plasma samples
from 14 patients with lung-cancer were depleted by High Select Top14 Abundant Protein Depletion Mini Spin Column (“Mini”), High Select
Top14 Abundant Protein Depletion Midi Spin Column (“Midi”; both Thermo Scientific), or by MARS-14 HPLC column (Agilent), targeting 14
proteins (“MARS”). The PCA scores plot shown for the first two components explain approximately 33% of the variance in the data. (A) Coloring
of samples according to individual from which the blood was drawn. (B) Coloring of samples according to plasma depletion method (Mini, Midi or
MARS). All samples (n = 42) and all variables detected in at least 50% of the samples were included in the analysis (n = 1811, 1% peptide and
protein FDR).
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potentially affect the depletion efficacy negatively, by altering
the epitopes though protein denaturation during the heating
procedure. An alternative approach would be to perform the
depletion of infected samples in an BSL3 environment and
then perform the heat inactivation on depleted plasma. In this
setting, the microcentrifuge spin columns have several
advantages as the centrifuge can easily be placed in a BSL3
environment and single-use columns are easy to disregard after
exposure to potentially infected material. Hence, we set out to
test the effect of heat inactivation, before (from here on
denoted “preHeat”) and after high abundant protein depletion
(from here on denoted “postHeat”) using the spin micro-
column and compare with the standard protocol (from here on
denoted “noHeat”). Heat inactivation at 56 °C for 30 min was
chosen, as this has previously shown to inactivate the SARS-
CoV-2 virus, with minimal impact on serological analysis.25
The experiment was performed in triplicates using plasma from
a healthy donor. In total 2062 proteins (1% protein and
peptide FDR, Table 1) was detected in the experiment.
To investigate whether the depletion efficacy was affected by
the heat treatment, we plotted the expression data of the
proteins supposedly removed in the depletion step (listed in
Table 1, Mini Spin column). We also plotted the remaining
bulk of proteins to see whether the observed differences were
limited to the “depleted proteins” or an overall effect on all
proteins. It was apparent that the difference between the heat-
treatment groups was related to the set of “depleted” proteins,
we could conclude that the efficacy of the depletion was
negatively affected by the heat-inactivation step (Figure 4A
left). The preHeat samples also showed a larger variability
overall (Figure 4A right), possibly due to precipitation caused
by the heating hampering the effectiveness of the depletion,
allowing high abundant proteins through and thereby
negatively affecting the detection of other lower abundant
proteins. In addition, a differential expression analysis showed
no major differences when comparing postdepletion heat
inactivation and no-heat inactivation plasma profiles, but major
differences when comparing predepletion heat inactivation and
Figure 3. Violin plots of the protein expression of the “depleted” proteins, for comparing the performance of the depletion of high-abundant plasma
proteins with either of the three methods. Protein expression as TMT relative rations (log2) are shown for (A) all proteins targeted by any of the
depletion methods, and the depletion targets subgrouped into (B) immunoglobulins and (C) the remaining depletion targets. Missing values,
presumably indicating proteins removed by the depletion were imputed “−1” (light gray box).
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Figure 4. Impact of heat-inactivation treatment on depletion efficacy. (A) Violin plots displaying the expression intensity distribution of the
proteins within the heat-inactivation study. The violin plots are filled in gray (left) for no heat-inactivation (“noHeat”), light green (middle) for
heat-inactivation prior to depletion (“preHeat”), and light green with fill pattern (right) for depletion after heat-inactivation of samples
(“postHeat”), respectively. The left figure shows the intensity distribution of proteins targeted by the depletion method and with measurable levels
(n = 41), as listed in Table 1. For protein identities (gene name) of depleted proteins and their individual expression, see Supporting Figure S3.
The right figure shows the intensity distribution of all other proteins detected (n = 1998). (B) Differential expression analysis comparing plasma
proteome profiles from plasma depleted without, before, and after heat-inactivation. Replicate plasma samples from the same individual was used.
(C) Principal components analysis (PCA), performed on data from both the depletion column study and the heat-inactivation study.
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no-heat-inactivation plasma profiles (Figure 4B). To visualize
the magnitude of the effect of heat inactivation in relation to
the known individual differences in protein expression, we
performed PCA analysis including all samples analyzed in the
current study (Figure 4C). Judging from the PCA, the samples
again cluster together regardless of depletion method, and
regardless of whether noHeat and postHeat. However, the
preHeat samples appeared different from the rest. Taken
together, it is clear that heating the crude plasma samples has a
major effect on the depletion efficacy, and hence also the
downstream proteomics results, and should be avoided. Heat
inactivation after the depletion, on the other hand, has minimal
effect on the proteome and could easily be performed in a
BSL3 environment.
Cross Species Compatibility
In vaccine and drug development, animal models like
cynomolgus macaques (Macaca fascicularis) are commonly
used in the early phases to test for efficacy and toxicity.
Macaque and human have a high degree of sequence
homology and hence, we wanted to explore if the depletion
spin columns were compatible with plasma from Macaca
fascicularis. Five replicates of plasma samples from 3 healthy
monkeys, including a pooled internal standard, were depleted
by High Select Top14 Abundant Protein Depletion Mini Spin
Columns and included in a TMTpro 16 plex-HiRIEF set. Prior
to digestion we separated the depleted samples on SDS-page
gels to get an overview of the depletion efficacy, here the
depleted Macaca samples showed similar patterns as seen on
gels with human depleted plasma samples, which was
encouraging (Supporting Figure S4, GEL IMAGES). Indeed,
in the downstream analysis, in total 2380 proteins (1% protein
and peptide FDR) were identified. Looking closer at the
targeted proteins, the effectiveness of the depletion was also
seen in the MS data (Figure 5). Overall, this shows that the
High Select Top14 Abundant Protein Depletion Mini Spin
Columns are compatible with plasma from Macaca fascicularis.
Figure 5. Cross species compatibility and reproducibility. The Mini depletion spin columns were applied on 5-plicate plasma samples from 3
Macaca fascicularis. (A) Violin plots showing protein expression distribution of total proteome, (B) all protein targets of depletion and all protein
targets of depletion subdivided into immunoglobulins and other plasma proteins, respectively. (C) Principal components analysis (PCA) applied to
the proteomics expression data.
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Reproducibility
Reproducibility and robustness of the method is of outmost
importance in plasma proteomics. We have previously shown
that when using the plasma HiRIEF LC-MS/MS protocol we
could obtain technical coefficient of variation (CV) of 4.7% on
peptide level, not including the depletion, buffer exchange, or
digestion steps. On the basis of the replicate Macaca fascicularis
samples (5 per individual animal) we also calculated the CV
within each individual animal to 11, 14, and 11 CV%,
respectively. To further explore the reproducibility, the
correlation between the individual replicates were calculated
for each of the animals. Spearman’s correlation coefficients
(R2) and statistical significance was calculated from the points.
In brief, median R2 was 0.82 (range: 0.70−0.96) Supporting
Figure S5, again showing high reproducibility of the workflow.
This shows that the depletion, buffer exchange, and digestion
steps together contribute to a large proportion of the
variability; however, the overall variability of the entire
workflow is still low.
■ CONCLUSION
The overall aim of the current study was to evaluate if single-
use spin columns for high abundant protein depletion could
provide a simple and time-efficient alternative to standard
HPLC columns, without compromising the analytical depth
and throughput. Second, we also wanted to evaluate if the spin
columns were compatible with viral inactivation through
heating and compatible with depletion of plasma from
macaque.
Here we show that the depleted plasma from the spin
columns can be subjected to viral deinactivation by heating
postdepletion without negatively effecting the proteome
coverage or reproducibility. As the spin columns do not
require any advanced equipment or handling, the depletion can
therefore easily be performed within the BSL3 setting. This is
of importance also for studies of other pathogens that can be
deactivated through heating. We also show that the proteome
coverage using the micro spin columns is on par with
traditional multiple-use HPLC columns and provides a flexible
and easy-to use alternative. Last, we show that the spin
columns are also effectively and reproducibly able to deplete
high abundant proteins from plasma samples from macaques,
thereby enabling in-depth plasma proteome analysis of this
important model animal.
In summary we conclude that the spin columns provide a
simple, reproducible, and cost-effective way to perform high
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